Search research articles
Contact Us
Filters
Showing results (181-190 of 196) with videos related to
Page
of 20
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 11, 2008
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma
Tomer Mark, Jessica Stern, Jessica R Furst, et al.
British Journal of Haematology
|
April 25, 2007
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
Paul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 23, 2009
Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement
Paul J Martin, Carlos R Bachier, Hans-Georg Klingemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2005
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13
William P Peters, Gary L Rosner, James J Vredenburgh, et al.
Blood Advances
|
April 9, 2024
Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients
Sanjeet S Dadwal, Rajat Bansal, Michael W Schuster, et al.
British Journal of Haematology
|
August 5, 2008
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma
Ruben Niesvizky, Paul G Richardson, S Vincent Rajkumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results
John P Leonard, Morton Coleman, Jamie C Ketas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2008
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
P Martin, A Chadburn, P Christos, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 15, 2009
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082
Lawrence B Marks, Constance Cirrincione, Thomas J Fitzgerald, et al.
Leukemia
|
January 18, 2008
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
J F San-Miguel, P G Richardson, P Sonneveld, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 196) with videos related to
Sort By:
Page
of 20
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 11, 2008
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma
Tomer Mark, Jessica Stern, Jessica R Furst, et al.
British Journal of Haematology
|
April 25, 2007
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
Paul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 23, 2009
Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement
Paul J Martin, Carlos R Bachier, Hans-Georg Klingemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2005
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13
William P Peters, Gary L Rosner, James J Vredenburgh, et al.
Blood Advances
|
April 9, 2024
Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients
Sanjeet S Dadwal, Rajat Bansal, Michael W Schuster, et al.
British Journal of Haematology
|
August 5, 2008
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma
Ruben Niesvizky, Paul G Richardson, S Vincent Rajkumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results
John P Leonard, Morton Coleman, Jamie C Ketas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2008
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
P Martin, A Chadburn, P Christos, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 15, 2009
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082
Lawrence B Marks, Constance Cirrincione, Thomas J Fitzgerald, et al.
Leukemia
|
January 18, 2008
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
J F San-Miguel, P G Richardson, P Sonneveld, et al.
Page
of 20